Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
 
 
 
Patent
Technical platform
  > Photodynamic technical platform  
  > Nano technical platform  
  > Genetic engineering technical platform  
  Oral solid preparation technical platform  
 
Oral solid preparation technical platform

        Oral solid dosage form is the most important type of preparation and is becoming the focus in nowadays drug R&D, whether small-molecule targeted drugs or special oral preparations. In the past few years, the group has gradually established the technical system of the platform in cooperation with a third-party, and been in the process of developing a number of new drugs and generic drugs with unique clinical treatment value. Oral solid formulation technology will be one of the basic technology platforms for the long-term development of the group.

The progresses of the projects based on the oral solid formulation platform are summarized as follows:
        Obeticholic acid for the treatment of liver diseases has officially launched bioequivalence study and plans to apply for drug registration as soon as possible. The project is a generic version of a drug in the United States for the treatment of primary biliary cirrhosis (PBC) which has been launched in global market. As a country with a high prevalence rate of liver diseases, China has a huge market. The company commissioned a third-party company to break through the patent restrictions of the original drug, and has obtained the corresponding patent authorization in mainland China.
        Besides, the Group has initiated pre-clinical study of a JAK1 selective inhibitor, as JAK-STAT pathway has been recognized of great therapeutic value for autoimmune diseases. We expect to find a new drug (me-better) with therapeutic advantages and will initiate an IND submission as soon as possible.

Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
(沪)-非经营性-2019-0143    沪ICP备10027510号-1